These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31376243)

  • 1. The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics.
    Bylsma LC; Dean R; Lowe K; Sangaré L; Alexander DD; Fryzek JP
    Cancer Med; 2019 Sep; 8(12):5800-5809. PubMed ID: 31376243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.
    Song X; Long SR; Barber B; Kassed CA; Healey M; Jones C; Zhao Z
    Curr Clin Pharmacol; 2012 Feb; 7(1):56-65. PubMed ID: 22299770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Liu T; Jiang S; Teng X; Zhong L; Liu M; Jin Y; Dong M
    Immunopharmacol Immunotoxicol; 2023 Feb; 45(1):1-9. PubMed ID: 35950851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
    Saif MW; Peccerillo J; Potter V
    Cancer Chemother Pharmacol; 2009 May; 63(6):1017-22. PubMed ID: 18781300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab).
    Miroddi M; Sterrantino C; Simmonds M; Caridi L; Calapai G; Phillips RS; Stewart LA
    Int J Cancer; 2016 Nov; 139(10):2370-80. PubMed ID: 27450994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
    Funakoshi T; Suzuki M; Tamura K
    Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions: a series of four case reports.
    Langerak A; River G; Mitchell E; Cheema P; Shing M
    Clin Colorectal Cancer; 2009 Jan; 8(1):49-54. PubMed ID: 19203897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
    Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infusion reactions to the chimeric EGFR inhibitor cetuximab--change to the fully human anti-EGFR monoclonal antibody panitumumab is safe.
    Resch G; Schaberl-Moser R; Kier P; Kopetzky G; Scheithauer W; Sliwa T; Greil R; Nösslinger T; Mayrbäurl B; Thaler J
    Ann Oncol; 2011 Feb; 22(2):486-7. PubMed ID: 21239398
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment.
    Saito Y; Uchiyama K; Takekuma Y; Komatsu Y; Sugawara M
    Support Care Cancer; 2023 Aug; 31(8):504. PubMed ID: 37528282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
    George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
    J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
    Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial).
    Akiyoshi K; Hamaguchi T; Yoshimura K; Takahashi N; Honma Y; Iwasa S; Takashima A; Kato K; Yamada Y; Onodera H; Takeshita S; Yasui H; Sakai G; Akatsuka S; Ogawa K; Horita Y; Nagai Y; Shimada Y
    Clin Colorectal Cancer; 2018 Mar; 17(1):e83-e89. PubMed ID: 29169974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer.
    Ketzer S; Schimmel K; Koopman M; Guchelaar HJ
    Clin Pharmacokinet; 2018 Apr; 57(4):455-473. PubMed ID: 28853050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.